Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
about
The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumorsEverolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data.Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewPazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.Advancements in pancreatic neuroendocrine tumors.Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.Emerging use of everolimus in the treatment of neuroendocrine tumors.Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.
P2860
Q26740374-E22A0A14-5989-4726-9163-0E54BDAFE133Q30884794-DD057D87-86C1-407D-A3B4-A4E0710AE804Q31170918-498FCD14-1450-4D87-9C2B-197A2DC7246EQ33422258-EE6B0CCD-7297-4782-94A4-2A5AA2E72D85Q36270115-45E22BD4-432B-403C-87EF-7554EA49D5F6Q36708349-6082D7BC-0C0C-4DAD-B3D7-EC43B04E54BBQ37091117-AFE9B65F-3A51-4A60-99C3-13A833CF21F8Q38125257-A5BE5993-E828-4B27-ABEE-EBA06DA8E773Q38250467-0FF44563-896B-4F98-8A53-F7F841ADD4D7Q38331666-A6B8A9D5-383C-4143-BE94-E6EE239D1864Q38661603-9566FC61-8DEE-4DB2-8F46-1459556AE3D2Q38842250-C3710146-DB0C-46FE-A612-87B7EBC38676Q48295398-1065242C-A845-44FA-8010-920E9C338860
P2860
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase I study of sorafenib in ...... dvanced neuroendocrine tumors.
@ast
Phase I study of sorafenib in ...... dvanced neuroendocrine tumors.
@en
type
label
Phase I study of sorafenib in ...... dvanced neuroendocrine tumors.
@ast
Phase I study of sorafenib in ...... dvanced neuroendocrine tumors.
@en
prefLabel
Phase I study of sorafenib in ...... dvanced neuroendocrine tumors.
@ast
Phase I study of sorafenib in ...... dvanced neuroendocrine tumors.
@en
P2093
P2860
P1476
Phase I study of sorafenib in ...... dvanced neuroendocrine tumors.
@en
P2093
Eileen Regan
Jennifer A Chan
Matthew H Kulke
Nadine Jackson
Paige Malinowski
Robert J Mayer
P2860
P2888
P304
P356
10.1007/S00280-013-2118-9
P577
2013-03-09T00:00:00Z
P6179
1007727375